News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarillo Biosciences (AMAR) Enters Into a License and Supply Agreement With CytoPharm for Low Dose Oral Interferon Use in Animal Diseases in China and Taiwan



3/25/2008 9:56:34 AM

AMARILLO, TX and TAIPEI, TAIWAN--(Marketwire - March 25, 2008) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has entered into a license and supply agreement (Agreement) with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company and specialty Clinical Research Organization in Taiwan specializing in pharmacogenomics.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES